John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Dublin, Oct. 20, 2016 -- Research and Markets has announced the addition of the "The Overview of Biosimilar Market in Japan ver2016" report to their offering.
The reader will understand overall trend of Japanese biosimilar market. The report covers market situation, pipeline, major players, and challenges and forecast of this market.
The market size for generics in 2012 was about 551 billion JPY. This was about 9% of the prescription drugs market as a whole. The generics market is estimated to grow to around 778 billion JPY in 2016.
The market for biosimilars was 4.5 billion JPY in 2012. A total of only three products including human growth hormone and erythropoietin were on the market by 2012. The market is expected to reach over 26 billion JPY by 2016.
Key Topics Covered:
1. Summary
2. Definition of biosimilar
3. Related Pharmaceutical Affairs
4. Market Size
5. Market Trends
6. Biosimilar Sales Items and Main Development Items (As of 2015)
7. Trends for Major Companies
8. Daiichi Sankyo
9. Nichi-Iko
10. Sanwa Kagaku
11. Mochida Pharmaceutical
12. Nippon Kayaku
13. Kissei
14. Boehringer Ingelheim
15. Future Development
16. Challenges and Forecast for Biosimilars
For more information about this report visit http://www.researchandmarkets.com/research/hbs5t6/the_overview_of
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biosimilars and Biosuperiors
